Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

A systematic literature review and meta-analysis of radioimmunotherapy consolidation for patients with untreated follicular lymphoma.

Rose AC, Shenoy PJ, Garrett G, Seward M, Kucuk RA, Doksansky H, Nastoupil LJ, Flowers CR.

Clin Lymphoma Myeloma Leuk. 2012 Dec;12(6):393-9. doi: 10.1016/j.clml.2012.09.012. Review.

PMID:
23158095
2.

90Yttrium-ibritumomab tiuxetan consolidation of first remission in advanced-stage follicular non-Hodgkin lymphoma: updated results after a median follow-up of 7.3 years from the International, Randomized, Phase III First-LineIndolent trial.

Morschhauser F, Radford J, Van Hoof A, Botto B, Rohatiner AZ, Salles G, Soubeyran P, Tilly H, Bischof-Delaloye A, van Putten WL, Kylstra JW, Hagenbeek A.

J Clin Oncol. 2013 Jun 1;31(16):1977-83. doi: 10.1200/JCO.2012.45.6400. Epub 2013 Apr 1.

PMID:
23547079
3.

Follicular lymphoma at relapse after rituximab containing regimens: comparison of time to event intervals prior to and after 90 Y-ibritumomab-tiuxetan.

Cicone F, Russo E, Carpaneto A, Prior JO, Delaloye AB, Scopinaro F, Ketterer N.

Hematol Oncol. 2011 Sep;29(3):131-8. doi: 10.1002/hon.968. Epub 2010 Sep 22.

PMID:
20862654
4.

Rationale for consolidation to improve progression-free survival in patients with non-Hodgkin's lymphoma: a review of the evidence.

Morschhauser F, Dreyling M, Rohatiner A, Hagemeister F, Bischof Delaloye A.

Oncologist. 2009;14 Suppl 2:17-29. doi: 10.1634/theoncologist.2009-S2-17. Review.

5.

FCR (Fludarabine, Cyclophosphamide, Rituximab) regimen followed by 90Yttrium ibritumomab tiuxetan consolidation for the treatment of relapsed grades 1 and 2 follicular lymphoma: a report of 9 cases.

Pisani F, Maini CL, Sciuto R, Dessanti L, D'Andrea M, Assisi D, Petti MC.

J Exp Clin Cancer Res. 2011 Feb 8;30:16. doi: 10.1186/1756-9966-30-16.

6.
7.

[Radioimmunotherapy in non-Hodgkin's lymphoma. With focus on anti-CD20 treatment].

de Nully Brown P, Jurlander J, Lindén O, Hansen M.

Ugeskr Laeger. 2005 Oct 10;167(41):3867-9. Danish.

PMID:
16221425
8.

Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.

Rajguru S, Kristinsdottir T, Eickhoff J, Peterson C, Meyer CM, Traynor AM, Kahl BS.

Clin Adv Hematol Oncol. 2014 Aug;12(8):509-15.

PMID:
25356575
9.

Phase III trial of consolidation therapy with yttrium-90-ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma.

Morschhauser F, Radford J, Van Hoof A, Vitolo U, Soubeyran P, Tilly H, Huijgens PC, Kolstad A, d'Amore F, Gonzalez Diaz M, Petrini M, Sebban C, Zinzani PL, van Oers MH, van Putten W, Bischof-Delaloye A, Rohatiner A, Salles G, Kuhlmann J, Hagenbeek A.

J Clin Oncol. 2008 Nov 10;26(32):5156-64. doi: 10.1200/JCO.2008.17.2015. Epub 2008 Oct 14.

PMID:
18854568
10.

Safety and efficacy of combination therapy with fludarabine, mitoxantrone, and rituximab followed by yttrium-90 ibritumomab tiuxetan and maintenance rituximab as front-line therapy for patients with follicular or marginal zone lymphoma.

Karmali R, Kassar M, Venugopal P, Shammo JM, Fung HC, Bayer R, O'Brien T, Gregory SA.

Clin Lymphoma Myeloma Leuk. 2011 Dec;11(6):467-74. doi: 10.1016/j.clml.2011.04.009. Epub 2011 Jun 22.

PMID:
21700527
11.

Fractionated ⁹⁰Y-ibritumomab tiuxetan radioimmunotherapy as an initial therapy of follicular lymphoma: an international phase II study in patients requiring treatment according to GELF/BNLI criteria.

Illidge TM, Mayes S, Pettengell R, Bates AT, Bayne M, Radford JA, Ryder WD, Le Gouill S, Jardin F, Tipping J, Zivanovic M, Kraeber-Bodere F, Bardies M, Bodet-Milin C, Malek E, Huglo D, Morschhauser F.

J Clin Oncol. 2014 Jan 20;32(3):212-8. doi: 10.1200/JCO.2013.50.3110. Epub 2013 Dec 2.

PMID:
24297953
12.

Tandem high-dose therapy in relapsed and refractory B-cell lymphoma: results of a prospective phase II trial of myeloablative chemotherapy, followed by escalated radioimmunotherapy with (131)I-anti-CD20 antibody and stem cell rescue.

Hohloch K, Sahlmann CO, Lakhani VJ, Wulf G, Glass B, Hasenkamp J, Meller J, Riggert J, Trümper L, Griesinger F.

Ann Hematol. 2011 Nov;90(11):1307-15. doi: 10.1007/s00277-011-1199-y. Epub 2011 Mar 1.

PMID:
21360108
13.

High-dose radioimmunotherapy versus conventional high-dose therapy and autologous hematopoietic stem cell transplantation for relapsed follicular non-Hodgkin lymphoma: a multivariable cohort analysis.

Gopal AK, Gooley TA, Maloney DG, Petersdorf SH, Eary JF, Rajendran JG, Bush SA, Durack LD, Golden J, Martin PJ, Matthews DC, Appelbaum FR, Bernstein ID, Press OW.

Blood. 2003 Oct 1;102(7):2351-7. Epub 2003 May 15.

14.

Radioimmunotherapy in follicular lymphoma.

Illidge T, Morschhauser F.

Best Pract Res Clin Haematol. 2011 Jun;24(2):279-93. doi: 10.1016/j.beha.2011.03.005. Epub 2011 May 12. Review.

PMID:
21658624
15.

A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.

Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M.

Ann Oncol. 2012 Feb;23(2):415-20. doi: 10.1093/annonc/mdr145. Epub 2011 May 2.

PMID:
21536660
16.

Safety and efficacy of (90) yttrium-ibritumomab-tiuxetan for untreated follicular lymphoma patients. An Italian cooperative study.

Ibatici A, Pica GM, Nati S, Vitolo U, Botto B, Ciochetto C, Petrini M, Galimberti S, Ciabatti E, Orciuolo E, Zinzani PL, Cascavilla N, Guolo F, Fraternali Orcioni G, Carella AM.

Br J Haematol. 2014 Mar;164(5):710-6. doi: 10.1111/bjh.12695. Epub 2013 Dec 17.

PMID:
24344981
17.

FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.

Lopci E, Santi I, Derenzini E, Fonti C, Savelli G, Bertagna F, Bellò M, Botto B, Huglo D, Morschhauser F, Zinzani P, Fanti S.

Ann Oncol. 2010 Sep;21(9):1877-83. doi: 10.1093/annonc/mdq024. Epub 2010 Feb 10.

PMID:
20147744
18.

Treatment recommendations for radioimmunotherapy in follicular lymphoma: a consensus conference report.

Witzig TE, Fishkin P, Gordon LI, Gregory SA, Jacobs S, Macklis R, McLaughlin P, Press O, Zelenetz AD.

Leuk Lymphoma. 2011 Jul;52(7):1188-99. doi: 10.3109/10428194.2011.570396. Epub 2011 May 23. Review.

PMID:
21599576
19.

Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.

Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, Pohlman BL, Bartlett NL, Wiseman GA, Padre N, Grillo-López AJ, Multani P, White CA.

J Clin Oncol. 2002 May 15;20(10):2453-63.

PMID:
12011122
20.

(90)Yttrium-ibritumomab-tiuxetan as first-line treatment for follicular lymphoma: 30 months of follow-up data from an international multicenter phase II clinical trial.

Scholz CW, Pinto A, Linkesch W, Lindén O, Viardot A, Keller U, Hess G, Lastoria S, Lerch K, Frigeri F, Arcamone M, Stroux A, Frericks B, Pott C, Pezzutto A.

J Clin Oncol. 2013 Jan 20;31(3):308-13. doi: 10.1200/JCO.2011.41.1553. Epub 2012 Dec 10.

PMID:
23233718

Supplemental Content

Support Center